MRNA Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -907.48% compared to Moderna's net margin of 19.72%. Moderna's return on equity of -29.23% beat Gilead Sciences's return on equity of 32.29%.

Moderna has a consensus price target of $47.59, signalling upside risk potential of 48.44%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 6.37%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Moderna has a beta of 1.845, which suggesting that the stock is 84.505% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. Moderna pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Moderna's net income of -$971M is lower than Gilead Sciences's net income of $1.3B. Notably, Moderna's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 23.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.97x versus 4.82x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -907.48% compared to Moderna's net margin of 23.32%. Moderna's return on equity of -29.23% beat Johnson & Johnson's return on equity of 30.18%.

Moderna has a consensus price target of $47.59, signalling upside risk potential of 48.44%. On the other hand Johnson & Johnson has an analysts' consensus of $170.92 which suggests that it could grow by 3.36%. Given that Moderna has higher upside potential than Johnson & Johnson, analysts believe Moderna is more attractive than Johnson & Johnson.

Moderna has a beta of 1.845, which suggesting that the stock is 84.505% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.30 per share. Moderna pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna quarterly revenues are $107M, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. Moderna's net income of -$971M is lower than Johnson & Johnson's net income of $5.5B. Notably, Moderna's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.97x versus 4.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -907.48% compared to Moderna's net margin of 21.68%. Moderna's return on equity of -29.23% beat Eli Lilly and's return on equity of 78.25%.

Moderna has a consensus price target of $47.59, signalling upside risk potential of 48.44%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Moderna has a beta of 1.845, which suggesting that the stock is 84.505% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Moderna pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna quarterly revenues are $107M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Moderna's net income of -$971M is lower than Eli Lilly and's net income of $2.8B. Notably, Moderna's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.97x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -907.48% compared to Moderna's net margin of 26.7%. Moderna's return on equity of -29.23% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Moderna has a consensus price target of $47.59, signalling upside risk potential of 48.44%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Moderna has higher upside potential than Regeneron Pharmaceuticals, analysts believe Moderna is more attractive than Regeneron Pharmaceuticals.

Moderna has a beta of 1.845, which suggesting that the stock is 84.505% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Moderna pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Moderna's net income of -$971M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Moderna's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.97x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.